Back to top

Stifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Hold rating on VistaGen Therapeutics, with a price target of $1.00. Matt...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

VistaGen Therapeutics, Inc. (VTGN)